{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-066746","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.824375+00:00","generated_at":"2026-06-01T07:28:28.044229+00:00","sec_items":["5.02","7.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Omega Therapeutics CMO Yan Moore departs; appoints Kaan Certel as Chief Business Officer","bullets":["CMO Yan Moore's employment terminated effective May 31, 2024; separation agreement with severance per employment agreement.","Company expects seamless continuation of Phase 1/2 trial for OTX-2002 (hepatocellular carcinoma); search for successor underway.","Appointed Kaan Certel, Ph.D. as Chief Business Officer effective May 28, 2024; over 20 years of biopharma experience.","Dr. Certel to lead global business development and strategic partnerships."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-066746","json":"https://secwatch.observer/filing/0000950170-24-066746.json","markdown":"https://secwatch.observer/filing/0000950170-24-066746.md","text":"https://secwatch.observer/filing/0000950170-24-066746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024066746/0000950170-24-066746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024066746/omga-20240528.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:28:28.044229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"224eb00d3c","claim":"Yan Moore departed as Chief Medical Officer at Omega Therapeutics, Inc..","evidence_excerpt":"On May 28, 2024, Omega Therapeutics, Inc. (the “Company”) and Yan Moore, M.D., the Company’s Chief Medical Officer, agreed to terminate his employment effective as of May 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024066746/0000950170-24-066746-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"agreed to terminate his employment"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}